Overall, AFP, DCP, and AFP-L3 persist as the most commonly used diagnostic biomarkers for HCC, while genomic alterations (TP53), immune markers (PD-L1, NLR), and liquid biopsy-based markers (ctDNA, miRNAs) are growing in popularity as diagnostic/prognostic tools. This evidence concerns the gene TP53 and hepatocellular carcinoma.